The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.
 
Matthew J. Frigault
Consulting or Advisory Role - Arcellx; Bristol-Myers Squibb/Juno; Bristol-Myers Squibb/Juno; Foundation Medicine (Inst); Gilead Sciences; Incyte; Novartis
Patents, Royalties, Other Intellectual Property - Own IP related to chimeric antigen receptors and T cell manufacturing
 
Elizabeth O'Donnell
No Relationships to Disclose
 
Noopur S. Raje
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Merck; Novartis; Takeda
Research Funding - Bluebird Bio (Inst)
 
Daniella Cook
Travel, Accommodations, Expenses - Adaptimmune
 
Andrew Yee
No Relationships to Disclose
 
Jacalyn Rosenblatt
Employment - Parexel
Honoraria - Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen; Celgene; Imaging Endpoints; Partner Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst)
Other Relationship - Dava Oncology
 
Chelsey Gibson
No Relationships to Disclose
 
Emma Logan
No Relationships to Disclose
 
David Avigan
Employment - Parexel
Consulting or Advisory Role - Aviv MedTech; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite/Gilead; Legend Biotech; Partner Therapeutics; Sanofi; Takeda; Takeda
Research Funding - Celgene; Kite, a Gilead company; Pharmacyclics
 
Michael Russell Bishop
Employment - UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - AGIOS; Arcellx; Arcellx; Autolus; Bluebird Bio; BMS; crispr therapeutics; Iovance Biotherapeutics; Kite, a Gilead company; Novartis; Seagen
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis
 
Katherine Eckert
No Relationships to Disclose
 
Heather Daley
No Relationships to Disclose
 
Diego Hernandez Rodriguez
No Relationships to Disclose
 
Andrew Mason
No Relationships to Disclose
 
Sarah Nikiforow
Consulting or Advisory Role - Iovance Biotherapeutics; Kite/Gilead; NKarta; Novartis
Travel, Accommodations, Expenses - NKarta
 
Carissa Mangus
No Relationships to Disclose
 
Aleksandra Gil-Krzewska
No Relationships to Disclose
 
Scott Currence
No Relationships to Disclose
 
Angela Shen
No Relationships to Disclose
 
Marcela Valderrama Maus
Leadership - Ichnos Sciences
Stock and Other Ownership Interests - Agenus; Century Therapeutics; TCR2 Therapeutics
Honoraria - BD Biosciences
Consulting or Advisory Role - Adaptimmune; Agenus; Alimera Sciences; arcellx; AstraZeneca; Bayer; Bluebird Bio; Bristol-Myers Squibb/Celgene; Cellectis; crispr therapeutics; EMD Serono; GlaxoSmithKline; Incysus; Kite, a Gilead company; MicroMedicine; Novartis; Takeda; TCR2 Therapeutics; Tmunity Therapeutics, Inc.; Torque; windmil
Research Funding - Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patents held by Massachusetts General Hospital/Partners Health care; all related to CAR T cells and/or gene therapy; Inventor on patents held by U. Pennsylvania with and without Novartis
Travel, Accommodations, Expenses - BD Biosciences; GlaxoSmithKline